_________________
May 17, 2016 | ValGenesis opened a new avenue of opportunity with a leading Plasma based product company that has implemented the paperless Validation Lifecycle Management System (VLMS) into their plasma donor collection centers.
As a widely recognized exam, the SOC 2 examination indicates that a service organization has been through an evaluation of their control activities as they relate to the applicable Trust Services Principles and Criteria.
The flexibility of ValGenesis’s automated workflow, form designer and process designer platform will make Validation, Risk and Change management processes easier while significantly reducing the time it takes to accomplish these tasks.
Since 2012, the ValGenesis organization has successfully continued its ISO 9001:2008 certification. In support of its efforts, ValGenesis has leveraged its own validation lifecycle management system platform to dynamically manage its corporate quality management system.
ValGenesis Inc, the market leader in enterprise Validation Lifecycle Management Software solutions, announced today that it has completed its Service Organization Controls 2 (SOC 2) examination under AT Section 101, Attest Engagements (AICPA, Professional Standards) for the period of January 1st 2014 through December 31st 2014.
ValGenesis provides a holistic view of the change control process and associated validation deliverables. All of the validation activities are accessible in real-time from a convenient dashboard within ValGenesis, which provides a direct line to validation tasks, inventory, work in progress, calendars, projects, reports, and a 360-degree view of GxP systems and assets by site.
ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Solutions (VLMS) announced that ScinoPharm Taiwan Ltd., a manufacturer of potent compound API and finished drug products, has implemented and successfully gone live with the ValGenesis VLMS 3.0 – Validation Lifecycle Management Solution to manage their validation lifecycle processes.
Dr. Hussain will advise ValGenesis’s senior management team to facilitate their efforts towards delivering state-of-the-art ValGenesis VLMS. Specifically his contributions will help to align further evolutions of ValGenesis VLMS to proactively deliver emerging regulatory requirements in the US and Globally.